Sumatriptan in clinical practice A 2-year review of 453 migraine patients

摘要: The long-term and within-patient consistency of the efficacy tolerability subcutaneous oral sumatriptan in migraine was studied by retrospective survey 2 years with mailed self-administered questionnaires our neurology outpatient clinic. Subjects were patients or without aura (N = 869). We measured use change over time headache relief, recurrence, chest symptoms after sumatriptan. questionnaire returned 735 (85%) patients; 453 had used for nearly 28,000 attacks during 25 (median) months (92% > 1 year). Sumatriptan provided mostly within hours, 85% at least two-thirds their attacks. Of all patients, 75% experienced (usually multiple) recurrences some 40% (nearly) Median to recurrence 8 12 hours (range 30). Recurrence reported as well. Over years, waned 18% (mainly because increase recurrence) improved 12% reduction adverse events relief); number monthly doses increased 20%, reduced 35%, not changed 45% patients. Chest occurred up 58% 42% attacks, causing discontinuation 10%. In total, 111 (25%) discontinued mainly events, insufficient high price. most effects consistent subjects time. rapid relief. Multiple major limitation. frequent but usually serious if forewarned.